Health Care Related Organization – Page 2

Thermo Fisher to Acquire Sanofi Factory; Amphastar Plans Major HQ Expansion

1 week ago talkbio0Tagged Acquisition, Amphastar, California, capacity quadruple, expansion, fill-finish, headquarters, pharmaceutical manufacturing, Ridgefield New Jersey, sanofi, sterile manufacturing, Thermo Fisher

Thermo Fisher; Sanofi; acquisition; sterile manufacturing; Ridgefield New Jersey; fill-finish; pharmaceutical manufacturing; Amphastar; headquarters expansion; capacity quadruple; California

AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup

1 week ago talkbio0Tagged Alexion, Amyloidosis, Anselamimab, AstraZeneca, Clinical trial failure, Drug Development, Infrequent, prespecified, Primary amyloidosis, Subgroup A Nepoviruses

AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development

Outsmarting Data Bottlenecks in Pharma: The Clinical Terminology Advantage

1 week ago talkbio0Tagged Aortic Valve Insufficiency, clinical terminology, data bottlenecks, Data Integration, Drug Industry, Interoperability, Pharma, Regulatory Compliance

data bottlenecks; clinical terminology; pharmaceutical industry; data integration; interoperability; regulatory compliance; AI in pharma; patient outcomes

Vertex, NHS England Finalize Reimbursement Deal for CF Drug Alyftrek

1 week ago talkbio0Tagged ALYFTREK, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation, Health care facility, NHS England, Nitroglycerin/Sodium Citrate/Ethanol Solution, Reimbursement, triple therapy, UK

Vertex; NHS England; Alyftrek; cystic fibrosis; reimbursement agreement; triple therapy; CFTR gene mutation; NICE; UK healthcare

AstraZeneca’s Baxdrostat Achieves Pivotal Phase 3 Success for Hypertension, Validating $1.3B CinCor Acquisition

1 week ago talkbio0Tagged Acquisition, AstraZeneca, baxdrostat, CinCor Pharma, Clinical Trials, Hypertensive disease, treatment-resistant hypertension, Uncontrolled

AstraZeneca; baxdrostat; CinCor Pharma; hypertension; high blood pressure; phase 3 trial; aldosterone synthase inhibitor; $1.3 billion acquisition; clinical trial win; uncontrolled hypertension; treatment-resistant hypertension

WHO to Develop Guidelines for Gilead’s Twice-Yearly HIV PrEP Injection (Lenacapavir)

1 week ago talkbio0Tagged Approved, Gilead, Guidelines, HIV Prevention, Lenacapavir, PREP gene, twice-yearly injection, United States Food and Drug Administration, World Health Organization

WHO; Gilead; Lenacapavir; twice-yearly injection; PrEP; HIV prevention; guidelines; FDA approval

EU Lifts Restriction on Valneva’s Chikungunya Vaccine for Older Adults, Recommends Caution

2 weeks ago talkbio0Tagged Adverse event, chikungunya vaccine, concerns, Elderly (population group), European Medicines Agency, Ixchiq, label extension, Safety, Valneva

Valneva; Chikungunya vaccine; IXCHIQ; European Medicines Agency; older adults; safety concerns; label extension; adverse events

Moderna’s COVID Vaccine Wins FDA Approval for At-Risk Young Children

2 weeks ago talkbio0Tagged Approved, At-Risk, Child, conditions, Covid Vaccine, Moderna, Spikevax, United States Food and Drug Administration

Moderna; FDA approval; COVID vaccine; children; at-risk; Spikevax; underlying conditions; full approval

Pfizer, Astellas’ Xtandi Combo Extends Survival in Early Prostate Cancer

2 weeks ago talkbio0Tagged Astellas, BCR, biochemical recurrence, Combined Modality Therapy, EMBARK, enzalutamide, leuprolide, Malignant neoplasm of prostate, nmHSPC, non-metastatic, Overall Survival, Pfizer, Xtandi

Pfizer; Astellas; Xtandi; Enzalutamide; prostate cancer; overall survival; combination therapy; leuprolide; non-metastatic hormone-sensitive prostate cancer (nmHSPC); EMBARK study; biochemical recurrence (BCR)

Merck Makes $10B Acquisition of Verona Pharma to Bolster Respiratory Portfolio

2 weeks ago talkbio0Tagged Acquisition, COPD, Drug Industry, Keytruda patent, Merck, Ohtuvayre, Pharma, Respiration Disorders, Verona

Merck; Verona Pharma; acquisition; Ohtuvayre; COPD; respiratory disease; Keytruda patent; biotech; pharmaceutical industry